18:30:14 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-14 Kvartalsrapport 2024-Q2
2024-03-07 Ordinarie utdelning DEMANT 0.00 DKK
2024-03-06 Årsstämma 2024
2024-02-06 Bokslutskommuniké 2023
2023-08-15 Kvartalsrapport 2023-Q2
2023-03-09 Ordinarie utdelning DEMANT 0.00 DKK
2023-03-08 Årsstämma 2023
2023-02-07 Bokslutskommuniké 2022
2022-08-16 Kvartalsrapport 2022-Q2
2022-03-11 Ordinarie utdelning DEMANT 0.00 DKK
2022-03-10 Årsstämma 2022
2022-02-08 Bokslutskommuniké 2021
2021-08-12 Kvartalsrapport 2021-Q2
2021-03-08 Ordinarie utdelning DEMANT 0.00 DKK
2021-03-05 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-08-17 Kvartalsrapport 2020-Q2
2020-03-11 Ordinarie utdelning DEMANT 0.00 DKK
2020-03-10 Årsstämma 2020
2020-02-04 Bokslutskommuniké 2019
2019-08-14 Kvartalsrapport 2019-Q2
2019-03-20 Ordinarie utdelning DEMANT 0.00 DKK
2019-03-19 Årsstämma 2019
2019-02-19 Bokslutskommuniké 2018
2018-08-15 Kvartalsrapport 2018-Q2
2018-03-23 Ordinarie utdelning DEMANT 0.00 DKK
2018-03-22 Årsstämma 2018
2018-02-22 Bokslutskommuniké 2017
2017-08-14 Kvartalsrapport 2017-Q2
2017-05-09 Kvartalsrapport 2017-Q1
2017-03-28 Ordinarie utdelning DEMANT 0.00 DKK
2017-03-27 Årsstämma 2017
2017-02-23 Bokslutskommuniké 2016
2016-11-10 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-25 Split DEMANT 1:5
2016-05-10 Kvartalsrapport 2016-Q1
2016-04-08 Ordinarie utdelning DEMANT 0.00 DKK
2016-04-07 Årsstämma 2016
2016-03-01 Bokslutskommuniké 2015
2015-11-12 Kvartalsrapport 2015-Q3
2015-08-14 Kvartalsrapport 2015-Q2
2015-05-07 Kvartalsrapport 2015-Q1
2015-04-10 Ordinarie utdelning DEMANT 0.00 DKK
2015-04-09 Årsstämma 2015
2015-02-26 Bokslutskommuniké 2014
2014-11-13 Kvartalsrapport 2014-Q3
2014-08-14 Kvartalsrapport 2014-Q2
2014-05-08 Kvartalsrapport 2014-Q1
2014-04-10 Ordinarie utdelning DEMANT 0.00 DKK
2014-04-09 Årsstämma 2014
2014-02-27 Bokslutskommuniké 2013
2013-11-05 Kvartalsrapport 2013-Q3
2013-08-14 Kvartalsrapport 2013-Q2
2013-05-07 Kvartalsrapport 2013-Q1
2013-04-10 Ordinarie utdelning DEMANT 0.00 DKK
2013-04-09 Årsstämma 2013
2013-02-26 Bokslutskommuniké 2012
2012-11-07 Kvartalsrapport 2012-Q3
2012-08-16 Kvartalsrapport 2012-Q2
2012-05-10 Kvartalsrapport 2012-Q1
2012-04-12 Ordinarie utdelning DEMANT 0.00 DKK
2012-04-11 Årsstämma 2012
2012-02-29 Bokslutskommuniké 2011
2011-11-10 Kvartalsrapport 2011-Q3
2011-08-19 Kvartalsrapport 2011-Q2
2011-05-12 Kvartalsrapport 2011-Q1
2011-04-14 Ordinarie utdelning DEMANT 0.00 DKK
2011-04-13 Årsstämma 2011
2010-11-16 Kvartalsrapport 2010-Q3
2010-04-08 Ordinarie utdelning DEMANT 0.00 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Demant är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av hörapparater och hörslingor. Idag innehar bolaget verksamhet på global nivå där produkterna säljs under varierande varumärken. Produkterna nås via bolagets distributörer och försäljningskanaler. Utöver huvudverksamheten bedriver bolaget forskning inom diagnostik för mätning av hörselkvalitén. Bolaget grundades ursprungligen under 1904 och har sitt huvudkontor i Smörum.
2022-01-25 08:30:00

25.1.2022 08:29:58 CET | Demant A/S | Investor News

Investor news                                                                                     25 January 2022

President of Oticon Medical Jes Olsen retires

 

Demant announces a change of leadership in its Hearing Implants business area, operating under the Oticon Medical brand. Jes Olsen, President of Oticon Medical, has decided to retire from the company at the beginning of March 2022, and Søren Nielsen, President & CEO of Demant, will take on the role as President of Oticon Medical until a replacement for Jes Olsen has been found. Jes Olsen, who has been with the Demant Group since 1985 and has spearheaded Oticon Medical since the establishment of the company in 2008, will continue in an advisory role for Oticon Medical to ensure a smooth transition.

 

“On behalf of the Demant Group, I would like to thank Jes Olsen for his great passion and his dedication to Demant and Oticon Medical for the past 36 years. I am very pleased that he will continue to support the Demant Group with his time, experience and network as a trusted advisor. With his immense knowledge of and experience from the hearing healthcare industry, Jes has supported many successful activities in the Demant Group from the early days when Oticon became a truly global company to our important step into hearing implants at the beginning of this millennium,” says Søren Nielsen, President & CEO of Demant.

 

“I am immensely proud to have been part of building Demant to where it is today, and I feel privileged to have been allowed to innovate and work with some of the smartest people I know. Working in different cultures internationally and seeing people grow and strong teams and results develop has been a fantastic experience for me, and I hope that I have made a difference for the Group. I would like to extend my thanks to everyone I have collaborated with during my many years with the Group, not least the many good colleagues in Oticon Medical for the last 15 years,” says Jes Olsen, President of Oticon Medical. 

 

Considering the important business development efforts and ambitious roadmap for Oticon Medical in 2022 and onwards, Søren Nielsen will take on the leadership of Oticon Medical for the time being in addition to his current responsibilities as CEO of Demant. In order to stay fully focused on implementing and verifying the solution to the issue relating to the recently announced voluntary field corrective action, Demant has chosen to postpone the appointment of a new President of Oticon Medical but will start the search in due course.

 

“Demant is fully committed to our Hearing Implants business and to developing and leading Oticon Medical successfully forward. It is part of our promise to users and professionals to continue to design and manufacture high-quality hearing implants, and I look forward to getting even closer to the daily operations of this business area,” says Søren Nielsen, President & CEO of Demant.

 

Resume, Jes Olsen

  • B.Sc. in acoustics and medico technology from the Technical University of Denmark
  • Employed with Demant since October 1985
  • 1985 Project Manager, Marketing, R&D, Oticon
  • 1993 General Manager, Oticon AB, Sweden
  • 1998 Director of Business and Product Development, “advanced products”, including Audiology, R&D and
    Marketing, Oticon
  • 2005 Director of R&D, Oticon
  • 2008-2022 President, Oticon Medical

 

 

Further information:

Søren Nielsen, President & CEO

Phone +45 3917 7300

www.demant.com

Other contacts:

Mathias Holten Møller, Head of Investor Relations

Trine Kromann-Mikkelsen, VP Corporate Communication and Relations

 

 

About Demant A/S

Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.

Attachments